SBFM_OUT_1 [2025-04-02 07:59:08 -0400] 3156 Bytes | 844 tokens | Cum: 844 tkns (10.55% of 8k)
==========================================================================

Alright, let’s light it up, because it's 7:59:07 AM on Wed Apr 02, 2025 -0400, and I'm charging into Sunshine Biopharma (SBFM), popping from 2.08 to 3.29. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Sunshine Biopharma (SBFM)
IPO: 2007-08-09 (17 Years Ago)
Market Cap: $5,633,349
Shares Outstanding: 2,710,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

Here's the first list of news for Sunshine Biopharma:

C1 - Apr-01-25 05:09PM - Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
C2 - Mar-25-25 09:06AM - Sunshine Biopharma signs agreement for rights to market two generic antibiotics
C3 - Mar-10-25 09:00AM - Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
C4 - Jan-21-25 08:00AM - Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
C5 - Jan-15-25 08:00AM - Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
C6 - Dec-09-24 07:30AM - Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
C7 - Dec-04-24 04:05PM - Sunshine Biopharma Launches a New Generic Prescription Drug
C8 - Dec-02-24 08:00AM - Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Prior AI Reports for SBFM:
1. 2025-04-01 – Score: 44 – Target: 3.1200 – Highs: – / – / –
despite-volatility-robust-sales-growth-indicates-potential-upside

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Sunshine Biopharma (SBFM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SBFM_OUT_3 [2025-04-02 07:59:11 -0400] 1098 Bytes | 269 tokens | Cum: 1115 tkns (13.94% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year**
Date: Apr-01-25 05:09PM
Source: (ACCESSWIRE)
URL: https://www.accesswire.com/viewarticle.aspx?id=1009116

The first and only All-in-one subscription platform offering
all of your PR Distribution and Media Outreach Tools in one
single solution.Monthly & Annual Subscriptions.

Find & create journalist lists with the most up to date database in the industry.

Personalize and customize your pitch for maximum engagement.

Discover your brand, industry, and competitor mentions.

The first and only All-in-one subscription platform that offers you the ability
to manage all of your IR communications needs from a single
source.Explore our IR subscriptions

Ensure your IR Site is accessible for your entire audience.

Experience seamless calls with our dedicated team of domestic operators.

Easily send y

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SBFM_OUT_5 [2025-04-02 07:59:11 -0400] 1020 Bytes | 305 tokens | Cum: 1468 tkns (18.35% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T10:20:23Z - Sunshine Biopharma, Inc. (SBFM) Stock Price, News, Quote & History - Yahoo Finance...
A2 - 2025-04-02T09:54:21Z - US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty A...
A3 - 2025-04-02T08:57:22Z - Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premark...
A4 - 2025-04-01T21:20:03Z - Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year By Investing.com...
A5 - 2025-04-01T21:14:00Z - Sunshine Biopharma Inc.: Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From La...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SBFM_OUT_7 [2025-04-02 07:59:15 -0400] 1098 Bytes | 285 tokens | Cum: 1755 tkns (21.94% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Sunshine Biopharma, Inc. (SBFM) Stock Price, News, Quote & History - Yahoo Finance**Date: 2025-04-02Source: {'uri': 'finance.yahoo.com', 'dataType': 'news', 'title': 'Yahoo! Finance'}URL: https://finance.yahoo.com/quote/SBFM/Sunshine Biopharma, Inc. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essentia

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SBFM_OUT_9 [2025-04-02 07:59:16 -0400] 943 Bytes | 291 tokens | Cum: 2145 tkns (26.81% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-04-17T17:36:19Z - Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B2 - 2024-04-17T14:07:53Z - Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
B3 - 2024-04-12T18:47:23Z - Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B4 - 2024-04-12T16:06:37Z - Gold Jumps Over 2%; Wells Fargo Earnings Top Views
B5 - 2024-04-05T17:06:12Z - Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B6 - 2024-04-02T10:05:00Z - Why the Risk With Penny Stocks is Worth the Reward

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SBFM_OUT_11 [2025-04-02 07:59:20 -0400] 1102 Bytes | 324 tokens | Cum: 2471 tkns (30.89% of 8k)
==========================================================================

Showing B2 (chunk 1 of 2): B2:
**Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/earnings/24/04/38293458/dow-surges-200-points-abbott-laboratories-posts-upbeat-earningsU.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.55% to 38,006.47 while the NASDAQ rose 0.24% to 15,903.38. The S&P 500 also rose, gaining, 0.40% to 5,071.74.
Check This Out: Alphabet, Toll Brothers And 2 Other Stocks Insiders Are Selling
 
Leading and Lagging Sectors
 
Materials shares rose by 1% on Wednesday.
In trading on Wednesday, real estate shares fell by 0.3%.
 
Top Headline
 
Abbott Laboratories (NYSE: ABT) reported better-than-expected earnings for its first quarter.
The company posted first-quarter sales of $9.96 billion, up 10.8%

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SBFM_OUT_13 [2025-04-02 07:59:21 -0400] 1046 Bytes | 245 tokens | Cum: 2803 tkns (35.04% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-01 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the pe...

S2 - 2025-04-01 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the pe...

S3 - 2025-04-01 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the pe...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SBFM_OUT_15 [2025-04-02 07:59:25 -0400] 1098 Bytes | 249 tokens | Cum: 3054 tkns (38.17% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods described. This discussion should be read in conjunction with our financial statements and the related notes included in this report. This discussion contains forward-looking statements. Please see Cautionary Note Regarding Forward-Looking Statements for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements.

Results of Operations

Comparison of Results of Operations for the fiscal years ended December 31, 2024 and 2023

During our fiscal year ended December 31, 2024, we generated revenues of $34,874,283, compared to revenues of $24,092,787 in 2023.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SBFM_OUT_17 [2025-04-02 07:59:35 -0400] 4222 Bytes | 1212 tokens | Cum: 4344 tkns (54.30% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+-------------------------+
| Volume: 1,353,589 | Perf Month: -9.96% | Option/Short: No / No | Sales Y/Y TTM: 61.94% |
+--------------------+-----------------------+-----------------------+-------------------------+
| Avg Volume: 87.23K | Perf Quarter: -32.03% | Short Float: 4.17% | ROE: -17.98% |
+--------------------+-----------------------+-----------------------+-------------------------+
| Rel Volume: 0.30 | Index: - | Short Ratio: 1.30 | ROI: -16.59% |
+--------------------+-----------------------+-----------------------+-------------------------+
| RSI (14): 44.26 | Market Cap: 5.63M | Short Interest: 0.11M | Sales Surprise: -28.52% |
+--------------------+-----------------------+-----------------------+-------------------------+
| ATR (14): 0.16 | Shs Outstand: 2.71M | Beta: 1.18 | EPS Surprise: 99.82% |
+--------------------+-----------------------+-----------------------+-------------------------+
| SMA20: -2.69% | Shs Float: 2.71M | Sales Q/Q: 41.59% | P/E: - |
+--------------------+-----------------------+-----------------------+-------------------------+
| SMA50: -13.36% | Inst Own: 6.08% | Sales past 5Y: - | Earnings: Nov 06 BMO |
+--------------------+-----------------------+-----------------------+-------------------------+
| SMA200: -39.80% | Insider Own: 0.08% | Employees: - | |
+--------------------+-----------------------+-----------------------+-------------------------+
| Perf Week: -2.35% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+--------------------+-----------------------+-----------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 8435178.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1197803.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.08
Average Volume: 91023.23
30-Day High: 2.39
30-Day Low: 1.91

[Detailed Financials: Q3 2024]
- Total Assets: $30,056,816.0
- Total Liabilities: $5,017,504.0
- Total Equity: $25,039,312.0
- Current Assets: $25,981,863.0
- Current Liabilities: $4,528,477.0

[Income Statement: Q3 2024]
- Revenue: $8,435,178.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.94

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-73,372

[Detailed Financials: Q2 2024]
- Total Assets: $29,300,978.0
- Total Liabilities: $5,811,114.0
- Total Equity: $23,489,865.0
- Current Assets: $25,748,520.0
- Current Liabilities: $5,299,478.0

[Income Statement: Q2 2024]
- Revenue: $9,303,067.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -9.94

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-5,289,886.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SBFM_OUT_19 [2025-04-02 07:59:37 -0400] 676 Bytes | 167 tokens | Cum: 4759 tkns (59.49% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SBFM_IN_21 [2025-04-02 07:59:37 -0400] 126 Bytes | 29 tokens | Cum: 4816 tkns (60.20% of 8k)
==========================================================================

====================================
[2025-04-02 07:59:37] # Analysis Completed
Elapsed Time: 30.25 seconds